Aptorum Group Ltd Class A (NASDAQ:APM) — Market Cap & Net Worth
Market Cap & Net Worth: Aptorum Group Ltd Class A (APM)
Aptorum Group Ltd Class A (NASDAQ:APM) has a market capitalization of $7.36 Million ($7.36 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27731 globally and #5643 in its home market, demonstrating a 1101.62% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aptorum Group Ltd Class A's stock price $8.32 by its total outstanding shares 6346823 (6.35 Million). See APM capex to operating cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
Aptorum Group Ltd Class A Market Cap History: 2018 to 2026
Aptorum Group Ltd Class A's market capitalization history from 2018 to 2026. Data shows change from $963.45 Million to $52.81 Million (-31.24% CAGR).
Index Memberships
Aptorum Group Ltd Class A is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #796 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #2561 of 3165 |
Weight: Aptorum Group Ltd Class A's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aptorum Group Ltd Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aptorum Group Ltd Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
36.03x
Aptorum Group Ltd Class A's market cap is 36.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $963.45 Million | $383.45K | -$14.83 Million | 2512.58x | N/A |
| 2019 | $1.01 Billion | $535.17K | -$18.69 Million | 1879.73x | N/A |
| 2020 | $156.77 Million | $911.51K | $7.07 Million | 171.99x | 22.18x |
| 2021 | $95.20 Million | $1.54 Million | -$25.05 Million | 61.74x | N/A |
| 2022 | $34.91 Million | $1.30 Million | -$9.80 Million | 26.94x | N/A |
| 2023 | $15.54 Million | $431.38K | -$2.83 Million | 36.03x | N/A |
Competitor Companies of APM by Market Capitalization
Companies near Aptorum Group Ltd Class A in the global market cap rankings as of August 3, 2026.
Key companies related to Aptorum Group Ltd Class A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Aptorum Group Ltd Class A Historical Marketcap From 2018 to 2026
Between 2018 and today, Aptorum Group Ltd Class A's market cap moved from $963.45 Million to $ 52.81 Million, with a yearly change of -31.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $52.81 Million | +684.91% |
| 2025 | $6.73 Million | -62.14% |
| 2024 | $17.77 Million | +14.35% |
| 2023 | $15.54 Million | -55.49% |
| 2022 | $34.91 Million | -63.33% |
| 2021 | $95.20 Million | -39.27% |
| 2020 | $156.77 Million | -84.42% |
| 2019 | $1.01 Billion | +4.41% |
| 2018 | $963.45 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Aptorum Group Ltd Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.36 Million USD |
| MoneyControl | $7.36 Million USD |
| MarketWatch | $7.36 Million USD |
| marketcap.company | $7.36 Million USD |
| Reuters | $7.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aptorum Group Ltd Class A
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small mol… Read more